Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4789143 | 1.00 | HRH4 (0.45) | HRH4HRH3GRIA1ADRB2HTR1B | |
| SCHEMBL2479475 | 1.00 | HRH4 (0.45) | HRH4HRH3GRIA1ADRB2HTR1B | |
| SCHEMBL19350614 | 1.00 | HRH4 (0.45) | HRH4HRH3GRIA1ADRB2HTR1B | |
| SCHEMBL754871 | 1.00 | HRH4 (0.45) | HRH4HRH3GRIA1ADRB2HTR1B | |
| SCHEMBL2600364 | 0.96 | HRH4 (0.43) | HRH4HRH3GRIA1ADRB2HTR1B | |
| SCHEMBL479263 | 0.89 | HRH4 (0.39) | HRH4HRH3ADRB2HTR1BNR2E1 | |
| SCHEMBL23841891 | 0.88 | EPHX1 (0.50) | HRH4HRH3GRIA1ADRB2EPHX1 | |
| SCHEMBL1026323 | 0.88 | EPHX1 (0.50) | HRH4HRH3EPHX1KDM4EALDH1A1 | |
| SCHEMBL23696489 | 0.88 | EPHX1 (0.50) | HRH4HRH3EPHX1KDM4EALDH1A1 | |
| SCHEMBL22458762 | 0.88 | EPHX1 (0.50) | HRH4HRH3GRIA1ADRB2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552990-B1 | POLYURETHANE/POLYUREA SPRAY ELASTOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2017-04-19 | — | — | EP | claimed |
| EP-2552990-A1 | POLYURETHANE/POLYUREA SPRAY ELASTOMERS | Dow Global Technologies LLC (US) | 2013-02-06 | — | — | EP | claimed |
| US-20130018147-A1 | POLYURETHANE/POLYUREA SPRAY ELASTOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-01-17 | — | — | US | claimed |
| WO-2011123241-A1 | POLYURETHANE/POLYUREA SPRAY ELASTOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2011-10-06 | — | — | WO | claimed |
| US-20240376246-A1 | ONE-POT PROCESS FOR THE PRODUCTION OF POLYCARBODIIMIDE CURED POLYMERS | BASF SE (DE) | 2024-11-14 | — | — | US | disclosed |
| EP-4402191-A1 | ONE-POT PROCESS FOR THE PRODUCTION OF POLYCARBODIIMIDE CURED POLYMERS | BASF SE (DE) | 2024-07-24 | — | — | EP | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230357776-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11732265-B2 | Compositions and methods for modulating complement factor B expression | IONIS PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2023041443-A1 | ONE-POT PROCESS FOR THE PRODUCTION OF POLYCARBODIIMIDE CURED POLYMERS | BASF SE (DE) | 2023-03-23 | — | — | WO | disclosed |
| US-20220017432-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | Reiley Pharmaceuticals, Inc. | 2022-01-20 | — | — | US | disclosed |
| US-20080004406-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2008-01-03 | — | — | US | disclosed |
| EP-1868987-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20070270566-A1 | Chain Extenders | ALBEMARLE CORPORATION (US) | 2007-11-22 | — | — | US | disclosed |
| US-7288677-B2 | Diimines and secondary diamines | ALBEMARLE CORPORATION (US) | 2007-10-30 | — | — | US | disclosed |
| US-20070073030-A1 | Chain Extenders | ALBEMARLE CORPORATION (US) | 2007-03-29 | — | — | US | disclosed |
| WO-2006104528-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060217567-A1 | Diimines and secondary diamines | ALBEMARLE CORPORATION | 2006-09-28 | — | — | US | disclosed |
| US-5155161-A | Living polymer modified by lactam, urea, amino ketone or aldehyde or thio analogs, followed by hydrolysis | NIPPON ZEON CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004406-A1 | DIIMINES AND SECONDARY DIAMINES | DDT, DDC, AOC1 | HRH4 110/4885HRH3 55/4885GRIA1 3396/4885 |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | HRH4 4261/4885HRH3 4228/4885GRIA1 4186/4885 |
| US-20070270566-A1 | Chain Extenders | DDC, PARG, ODC1 | HRH4 1807/4885HRH3 1716/4885GRIA1 3880/4885 |
| US-20220017432-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | PTGES3, PTGES, HPGDS | HRH4 2009/4885HRH3 2428/4885GRIA1 782/4885 |
| US-20060217567-A1 | Diimines and secondary diamines | DDT, DDC, AOC1 | HRH4 110/4885HRH3 55/4885GRIA1 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.